

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Proposed Single Technology Appraisal

## Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Lupin Healthcare (mexiletine)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Arthritis &amp; musculoskeletal Alliance</li> <li>• Disability Rights UK</li> <li>• Genetic Alliance UK</li> <li>• Leonard Cheshire Disability</li> <li>• Muscular Dystrophy UK</li> <li>• Muslim Council of Britain</li> <li>• Myotonic Dystrophy Support Group</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British Heart Rhythm Society</li> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Myology Society</li> <li>• British Orthopaedic Association</li> <li>• British Society for Genetic Medicine</li> <li>• British Society of Rehabilitation Medicine</li> <li>• Chartered Society of Physiotherapy</li> <li>• Primary Care Respiratory Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare Limited</li> <li>• Aurobindo Pharma – Milpharm Ltd</li> <li>• GlaxoSmithKline UK</li> <li>• Mylan</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Cystic Fibrosis and Genetic Disorders Group</li> <li>• Cochrane Musculoskeletal Group</li> <li>• Genomics England</li> <li>• John Walton Muscular Dystrophy Research Centre</li> <li>• MRC Centre for Neuromuscular Diseases</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<u>Others</u> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS East and North Hertfordshire CCG</li> <li>• NHS England</li> <li>• NHS Southern Derbyshire CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• North Star Clinical Network</li> <li>• National Institute for Health Research</li> <li>• TREAT-NMD</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• National Congenital Anomaly and Rare Disease Registration Service, Public Health England</li> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.